RAD51 has proved to be a predictive marker to therapeutic responses in various cancers, including platinum-based chemotherapy benefit in breast cancer [16], esophageal squamous cell carcinoma [18], PARP inhibitor benefit in pancreatic cancer [19] and prostate cancer [20]. This evidence concerns the gene RAD51 and breast carcinoma.